Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Exp Immunol ; 187(2): 316-324, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27774628

ABSTRACT

Regulatory T cell (Treg ) therapy has been exploited in autoimmune disease, solid organ transplantation and in efforts to prevent or treat graft-versus-host disease (GVHD). However, our knowledge on the in-vivo persistence of transfused Treg is limited. Whether Treg transfusion leads to notable changes in the overall Treg repertoire or whether longevity of Treg in the periphery is restricted to certain clones is unknown. Here we use T cell receptor alpha chain sequencing (TCR-α-NGS) to monitor changes in the repertoire of Treg upon polyclonal expansion and after subsequent adoptive transfer. We applied TCR-α-NGS to samples from two patients with chronic GVHD who received comparable doses of stem cell donor derived expanded Treg . We found that in-vitro polyclonal expansion led to notable repertoire changes in vitro and that Treg cell therapy altered the peripheral Treg repertoire considerably towards that of the infused cell product, to different degrees, in each patient. Clonal changes in the peripheral blood were transient and correlated well with the clinical parameters. We suggest that T cell clonotype analyses using TCR sequencing should be considered as a means to monitor longevity and fate of adoptively transferred T cells.


Subject(s)
Graft vs Host Disease/diagnosis , Hematopoietic Stem Cell Transplantation , Immunotherapy, Adoptive/methods , Receptors, Antigen, T-Cell, alpha-beta/genetics , T-Lymphocytes, Regulatory/physiology , Cell Proliferation , Cells, Cultured , Female , Graft vs Host Disease/prevention & control , High-Throughput Nucleotide Sequencing , Humans , Male , Middle Aged , Prognosis , T-Lymphocytes, Regulatory/transplantation , Transplantation, Homologous , Treatment Outcome
2.
Horm Metab Res ; 47(1): 48-55, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25372776

ABSTRACT

Cord blood has been used as a cell source for therapeutic purposes in children with type 1 diabetes and other disorders. Here, we explore the benefits of cord blood as an autologous source of T regulatory cells for immune cell therapy in patients. CD4(+)CD25(+) T regulatory cells were isolated from cord blood and adult peripheral blood of healthy donors and compared during and after expansion in a 14-day protocol incorporating anti-CD3/anti-CD28 beads, and IL-2 with or without rapamycin. Cord blood T regulatory cells were largely naïve (89±7 vs. 31±10% in young adults, p<0.0001), and had higher expansion yields (median 5,968-fold) than adult T regulatory cells (median 516-fold, p=0.001) and adult naïve T regulatory cells (median 820-fold, p=0.003). Rapamycin reduced expansion yields, but was not necessary to obtain pure expanded cord blood T regulatory cells as judged by FOXP3 staining (94±3%), methylation status of FOXP3 (97%), and intracellular effector cytokine staining (< 6%). Expanded adult T regulatory cells were much less pure in the absence of rapamycin (72±19% FOXP3; 76% by methylation status, <13% INF-γ, <16% IL-4, <5% IL-17 positive), but purity was achieved by inclusion of rapamycin during expansion. Despite differences in purity, all preparations of expanded T regulatory from all sources were able to strongly suppress proliferation of T effector cells in vitro. Our findings suggest that cord blood is an excellent source of T regulatory cells for expansion and autologous cell therapy that may be considered as a strategy to prevent immune-mediated destruction of beta cells in type 1 diabetes.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Fetal Blood/cytology , T-Lymphocytes, Regulatory/cytology , Adolescent , Adult , CD4 Antigens/metabolism , Cell Count , Cell Proliferation , Cell Separation , Humans , Interleukin-2 Receptor alpha Subunit/metabolism , Phenotype , T-Lymphocytes, Regulatory/immunology , Transplantation, Autologous , Young Adult
3.
Br J Cancer ; 109(3): 714-22, 2013 Aug 06.
Article in English | MEDLINE | ID: mdl-23799849

ABSTRACT

BACKGROUND: Besides the conventional clear-cell renal cell carcinoma (ccRCC), papillary RCC (pRCC) is the second most common renal malignancy. Papillary RCCs can further be subdivided into two distinct subtypes. Although a clinical relevance of pRCC subtyping has been shown, little is known about the molecular characteristics of both pRCC subtypes. METHODS: We performed microarray-based microRNA (miRNA) expression profiling of primary ccRCC and pRCC cases. A subset of miRNAs was identified and used to establish a classification model for ccRCC, pRCC types 1 and 2 and normal tissue. Furthermore, we performed gene set enrichment analysis with the predicted miRNA target genes. RESULTS: Only five miRNAs (miR-145, -200c, -210, -502-3p and let-7c) were sufficient to identify the samples with high accuracy. In a collection of 111 tissue samples, 73.9% were classified correctly. An enrichment of miRNA target genes in the family of multidrug-resistance proteins was noted in all tumours. Several components of the Jak-STAT signalling pathway might be targets for miRNAs that define pRCC tumour subtypes. CONCLUSION: MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , MicroRNAs/genetics , Carcinoma, Renal Cell/classification , Carcinoma, Renal Cell/pathology , Cohort Studies , Gene Expression Profiling , Humans , Kidney Neoplasms/classification , Kidney Neoplasms/pathology , MicroRNAs/biosynthesis , Principal Component Analysis
4.
Aliment Pharmacol Ther ; 21(10): 1231-9, 2005 May 15.
Article in English | MEDLINE | ID: mdl-15882244

ABSTRACT

BACKGROUND: The protective role of Helicobacter pylori in gastro-oesophageal reflux disease has been widely discussed. AIM: To assess the risk of reflux oesophagitis in patients with functional dyspepsia after treatment for H. pylori infection. METHODS: A randomized, placebo-controlled, investigator-blinded trial was carried out on 157 functional dyspeptic patients. Patients were randomized to receive lansoprazole, amoxicillin and clarithromycin (antibiotic group) or lansoprazole and identical antibiotic placebos (control group). Upper gastrointestinal endoscopy was performed at baseline, 3 and 12 months after randomization. The primary aim was to detect the presence of reflux oesophagitis. Analyses were performed on an intention-to-treat basis. RESULTS: A total of 147 patients (94%) and 133 (85%) completed 3 months and 12 months follow-up, respectively. The eradication rate of H. pylori was 90% in the antibiotic group (74 of 82) and 1% (one of 75) in the control group. At 3 months, reflux oesophagitis was diagnosed in 3.7% (three of 82) in the antibiotic group and 4% (three of 75) in the control group (P > 0.2). At 12 months, diagnosis was established in five new cases within the first group and in four within the second (P > 0.2). No difference was found in heartburn symptoms. CONCLUSIONS: H. pylori eradication does not cause reflux oesophagitis in this western population of functional dyspeptic patients.


Subject(s)
Dyspepsia/microbiology , Esophagitis, Peptic/etiology , Helicobacter Infections/drug therapy , Helicobacter pylori , Omeprazole/analogs & derivatives , 2-Pyridinylmethylsulfinylbenzimidazoles , Adolescent , Adult , Aged , Amoxicillin/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination/therapeutic use , Dyspepsia/complications , Dyspepsia/drug therapy , Esophagitis, Peptic/microbiology , Follow-Up Studies , Heartburn/complications , Helicobacter Infections/complications , Humans , Lansoprazole , Middle Aged , Omeprazole/therapeutic use , Risk Assessment , Single-Blind Method
5.
Eur J Pediatr ; 151(2): 117-20, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1371465

ABSTRACT

Peroxisomal disorders are genetic diseases in which an impairment in one or more peroxisomal function(s) causes clinical and multiple biochemical abnormalities. Early recognition of the major peroxisomal disorders in which functional peroxisomes are virtually absent, leading to a generalised impairment of peroxisomal functions, is of utmost importance, as this will enable the prenatal diagnosis of these severe diseases in future pregnancies. Unfortunately, clinical recognition of these disorders can be difficult because of the aspecific and varying phenotypic presentation. We analysed the clinical characteristics in 40 patients suspected of having a peroxisomal disorder to identify specific clinical criteria for diagnosis. From this study we conclude that the combined presence of at least three major clinical characteristics (present in greater than 75% of the affected patients, including psychomotor retardation, hypotonia, impaired hearing, low/broad nasal bridge, abnormal ERG, hepatomegaly) and one or more minor characteristics (present in 50%-75% of the patients, like large fontanelles, shallow orbital ridges, epicanthus, anteverted nostrils, retinitis pigmentosa) warrants biochemical investigation of peroxisomal functions. Further prospective investigations will have to be done to evaluate these criteria.


Subject(s)
Metabolism, Inborn Errors/diagnosis , Microbodies , Zellweger Syndrome/diagnosis , Adrenoleukodystrophy/diagnosis , Biochemical Phenomena , Biochemistry , Chondrodysplasia Punctata/diagnosis , Diagnosis, Differential , Humans , Metabolism, Inborn Errors/metabolism , Prenatal Diagnosis , Refsum Disease/diagnosis , Retrospective Studies , Zellweger Syndrome/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...